Gastric Electrical Stimulation

Last Review Date: January 8, 2021     Number: MG.MM.SU.57C4a

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Gastric electrical stimulation (GES) has been developed as an alternative treatment for refractory gastroparesis. The device consists of 4 components: the implanted pulse generator, 2 intramuscular stomach leads, a stimulator programmer and a memory cartridge. The leads are implanted surgically using an open or laparoscopic technique and are connected to the pulse generator that is implanted in a subcutaneous pouch. The device delivers timed impulses to the gastric muscles that are intended to stimulate gastric myoelectric activity, with the goal of improving stomach emptying and relieving the symptoms of nausea and vomiting.

GES has also been proposed as an alternative to bariatric surgery for the treatment of obesity. The technique for implantation of the device is the same for treating gastroparesis but utilizes different stimulation parameters and a different location for placement of electrodes on the stomach wall. GES in the obese patient is thought to induce early satiety, but it is not known whether this is caused by stimulation of the nerves, inhibition of hormones or stimulation of the stomach muscle itself. (See Limitations/Exclusions)

Guideline

GES is considered medically necessary for the treatment of chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

The following criteria must be met:

1. Significantly delayed gastric emptying as evidenced by standard scintigraphic imaging of solid food
2. Member is refractory or intolerant to both:
   a. Prokinetic medications (2 out of 3 classes)
   b. Antiemetic medications (2 out of 3)
3. Significantly poor nutritional status, as evidenced by weight loss of 10% of body weight (for height and age in comparison with pre-illness weight)

Table 1: Prokinetic Medications
### Table 2: Antiemetic Medications

<table>
<thead>
<tr>
<th>Class</th>
<th>Common Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihistamines</strong></td>
<td>diphenhydramine (Benadryl®), dimenhydrinate (Dramamine®), meclizine (Antivert®), hydroxyzine (Vistaril®), trimethobenzamide (Tigan®)</td>
</tr>
<tr>
<td><strong>Serotonin (5HT3) receptor antagonists</strong></td>
<td>ondansetron (Zofran®), granisetron (Kytril®), dolasetron (Anzemet®)</td>
</tr>
<tr>
<td><strong>Dopamine receptor antagonists</strong></td>
<td>Metoclopramide (Reglan®), perphenazine (Trilafon®), prochlorperazine (Compazine®), promethazine (Phenergan®), thiethylperazine (Torecan®), cyclizine (Marezine®)</td>
</tr>
</tbody>
</table>

### Limitations/Exclusions

1. GES is not considered medically necessary for gastrointestinal dysmotility disorders other than gastroparesis, obesity (or any other indication not listed above) due to insufficient evidence of therapeutic value.

2. The Medtronic Enterra® Therapy System, a high frequency electronic device, is currently FDA approved under the FDA’s Humanitarian Device Exemption (HDE) program. No other GES system for treating gastroparesis has been approved to date. Therefore, requests for alternate GES systems (e.g., gastric pacing, neural gastric electrical stimulation) will be denied as not medically necessary due to insufficient evidence of therapeutic value.

### Revision History

| Jan. 8, 2021 | Changed decrease of “≤ 90% of normal body weight” (as evidence of significantly poor nutritional status) to “weight loss of 10% of body weight” |

### Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>43647</td>
<td>Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum</td>
</tr>
<tr>
<td>43648</td>
<td>Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum</td>
</tr>
<tr>
<td>43881</td>
<td>Implantation or replacement of gastric neurostimulator electrodes, antrum, open</td>
</tr>
<tr>
<td>43882</td>
<td>Revision or removal of gastric neurostimulator electrodes, antrum, open</td>
</tr>
<tr>
<td>64590</td>
<td>Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
<tr>
<td>64595</td>
<td>Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver</td>
</tr>
</tbody>
</table>
Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming

Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming

Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming

Implantable neurostimulator, pulse generator, any type

Implantable neurostimulator electrode, each

Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only

Implantable neurostimulator radiofrequency receiver

Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver

Implantable neurostimulator pulse generator, single array, rechargeable, includes extension

Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension

Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension

Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension

External recharging system for battery (internal) for use with implantable neurostimulator, replacement only

References


